A lzheimer's disease (AD) is an age-related neurodegenerative disease that is the leading cause of dementia. As the initiating pathological factor in AD etiology, abnormal amyloid-b (Ab) accumulation is considered to induce a cascade of events, including oxidative damage, inflammation, neurodegeneration, and cognitive impairment (1, 2) . Currently, the failure of antiAb therapies in patients with AD suggests that exogenous Ab inhibitors could be ineffective in these patients (3) . Therefore, identifying the endogenous modulator of Ab information may provide novel therapeutic approaches to the disease. Clinical literatures readily recognize that females have a higher risk for AD, and most studies have focused on the regulation of female sex steroids on Ab metabolism (4) (5) (6) , with less emphasis on the role of androgens (testosterone or DHT). Emerging clinical observations and experimental studies have demonstrated that age-related loss of androgens in males is associated with Ab deposition in the brain that may contribute to vulnerability to AD (7) (8) (9) , but whether there exists a causal relationship is still unknown. It is generally accepted that androgens serve as endogenous negative regulators of Ab accumulation (10) . However, the mechanism underlying this androgen action is still not completely understood. This review summarizes the relationship between androgen and Ab accumulation in males and the mechanism of androgen in regulating Ab production, degradation, and clearance, as well as the neuroprotective role of androgens against Ab-induced oxidative damage and neuronal apoptosis. Understanding these effects of androgens on Ab metabolism and toxicity may provide valuable insights into the etiology of AD and thus therapeutic strategies for the disease.
Androgen Levels and Ab Deposition

Clinical observations
The relationship between serum concentrations of androgens and Ab protein has been investigated in several clinical observations (Table 1) . Testosterone is the predominant androgen, and there are three types of testosterone in the blood: sex hormone binding globulinbound testosterone, albumin-bound testosterone, and free testosterone, the latter two of which have bioactivity and thus are collectively called bioavailable testosterone (16) . In men with memory loss or dementia, both serum total and free testosterone are inversely correlated with plasma Ab 1-40 levels, suggesting the effect of androgen on Ab levels (11) . In parallel to this finding, testosterone withdrawal by androgen deprivation therapy (ADT) in men with prostate cancer is associated with increases in plasma levels of Ab, which could affect cognitive performance of these patients and increase the risk of developing AD (12, 13, 17) . Although conflicting results have been reported and the exact role of ADT in cognitive function in patients with prostate cancer is unclear (18, 19) , several most recent meta-analyses have drawn the consistent conclusion that ADT is associated with an increased risk of overall cognitive impairment and dementia (20, 21) . Therefore, it can be speculated that low plasma testosterone levels make the brain more predisposed to pathogenic agents of AD, including Ab and t toxicity. Moreover, alteration of androgen levels in the brain is connected with Ab pathology. For example, a radioimmunoassay study reported that men with mild AD-related pathology showed a significant reduction of testosterone levels that was inversely correlated with soluble Ab concentrations in the brain (14) , indicating that testosterone might affect early neuropathological changes in AD. Consistently, serum free testosterone levels were negatively correlated with both circulating Ab levels and brain amyloid burden in mild cognitive impairment (MCI), a transitional state between normal aging and developing AD (8) . Thus, these results indicate that androgens could have an impact on Ab levels in the early stage of AD. Of interest, it has been demonstrated that testosterone influenced ;the plasma Ab 1-40 /Ab 1-42 ratio (8), a promising surrogate biomarker for brain Ab burden (22) . Because plasma Ab levels change with AD progression, the utility of plasma Ab as an indicator of AD is controversial. Thus, the value of understanding how testosterone affects AD through the plasma Ab ratio or cerebral amyloid deposition needs to be further evaluated.
Conversely, a recent study observed that the level of serum free testosterone was related to brain Ab positivity in females but not in males (15) . One explanation is that there might exist a higher threshold level of testosterone for anti-Ab deposition in males than in females, because testosterone levels in females are far lower than in males. In addition, it should be noted that in this study, females with MCI number more than males (approximately two times), whose Ab pathology is predisposed to be affected by testosterone. Therefore, whether there exists a sex difference of Ab load in the MCI brain needs to be investigated.
Experimental studies
Consistent with observations in humans, animal studies have associated androgen deficiency with extensive Ab pathology ( Table 2 ). In normal young rats and guinea pigs, testosterone depletion induced by gonadectomy elevated Ab levels in both brain and plasma (28, 29) . With the prolongation of androgen deprivation time (10 months) in young mice, orchiectomy can accelerate brain aging, indicated by a neurotrophin decrease, hippocampal neuron loss, and Ab deposition (30) . These findings indicate that acute or chronic androgen depletion by gonadectomy might lead to susceptibility of the male brain to Ab deposition. This result is further demonstrated in aging rodents. For example, DHT level lowering with normal aging in male Brown Norway rats was associated with a significant increase of Ab level in the brain (31) . Compared with the adult counterparts, old male mice were shown to have higher levels of amyloid precursor protein (APP) mRNA and protein in the cerebral cortex, thus implying subsequent Ab production (32) . Furthermore, in aged hypogonadal mice, Ab and proteolytic fragments of APP accumulated in the male brain but not in the female brain, suggesting that age-related androgen loss specifically promoted the development of AD pathology (33) . Thus, these findings reveal that age-related androgen depletion is involved in Ab pathology of AD. In addition, in 3xTg-AD mice, an animal model of AD with three transgenes (APPswe, PS1M146V, and Tau P301L), androgen withdrawal aggravated Ab toxicity. Several studies have shown that reduction of testosterone via orchidectomy or using a gonadotropinreleasing hormone inhibitor significantly accelerated Ab deposition in the brain of male 3xTg-AD mice (9, 23, 24) , thus leading to behavioral impairment (23) . With demasculinization during the neonatal stage, these mice exhibit significantly elevated Ab accumulation in adulthood, suggesting that neonatal androgen may program vulnerability to amyloid pathology (25) . The change in brain androgen levels with aging is also associated with Ab accumulation and gliosis in aged male 3xTg-AD mice (34) . Together, these results indicate that androgen loss in male rodents has an impact on Ab pathology.
In conclusion, current evidence from clinical observations and animal research demonstrated that low testosterone levels are related to an increase of Ab levels in the brain and body fluid. This inverse relationship between testosterone levels and Ab deposition is mainly present in the MCI population, which suggests that the protective role of androgens could be exerted in the early stage of AD. However, whether it is the causality is still unclear. A previous study confirmed that testosterone loss precedes the clinical diagnosis of AD (35) , suggesting that low testosterone is a risk factor for AD rather than a result of the disease. In addition, several studies found that AD pathologies can affect steroidogenesis in the brain (36) (37) (38) . Thus, it can be concluded that androgen loss and AD progression interact with each other, but more studies are needed to demonstrate the effects of AD on androgen production.
Ab processing
In physiological condition, the level of Ab in the brain remains stable due to a balance in its production and clearance ( Fig. 1 ). Ab is generated from the proteolytic processing of the transmembrane APP. The APP molecule can be processed by two competing pathways, the amyloidogenic and nonamyloidogenic pathways (39) . In the amyloidogenic pathway, APP is cleaved by the protease b-secretase 1 that binds to the b-sites of the APP and thus results in the release of soluble APPb and membrane-bound C99. The C99 fragment is sequentially cleaved by the g-secretase/presenilin complex at the g-sites, generating Ab peptides that are mainly 40 (Ab ) and 42 (Ab ) amino acids in length. In the nonamyloidogenic pathway, APP is cleaved by the a-secretase within the Ab domain at the a-sites, which produces soluble APPa but not Ab or Ab 1-42 peptides. Excessive Ab peptides can be degraded by several crucial enzymes, including neprilysin (NEP) and insulindegrading enzyme (IDE) (40) . These Ab degraded fragments are removed from the brain through several mechanisms, including the blood-brain barrier (BBB) and cerebrospinal fluid (CSF) clearance, as well as immune phagocytosis (7, 41, 42) . Disruption of Ab processing can lead to the accumulation and aggregation of Ab.
Effects of Androgens on Ab Processing
Production
Evidence from studies in vitro has demonstrated that androgens can regulate Ab production via affecting several proteolytic enzymes in APP processing. In primary neuronal cells and neuroblastoma (N2a) cells transfected with bAPP 695 , testosterone promoted cell viability and the secretion of neurotrophic soluble APPa, thus decreasing Ab formation (43, 44) . These studies Male Wistar rat Adult (3 mo) 6 T or F T↓ Ab 1-42 levels; blocked by F Huo et al. (27) indicate that testosterone regulates the Ab levels through the a-secretase pathway. Also, in male APP 23 mice, the AD-like transgenic model, elevation of endogenous testosterone by genetic disrupting aromatase results in a significant reduction of Ab accumulation, which is associated with a downregulation of b-secretase 1 (26) . In contrast with the Ab-lowering role of testosterone, a study found that supplementation of exogenous testosterone to old male and castrated mice gave rise to increased presenilin, which could elevate the expression and activity of g-secretase and thus possibly lead to Ab accumulation (45) . These results suggest that testosterone can modulate Ab generation through the amyloidogenic pathway.
Degradation
Androgens can also influence Ab degradation by regulation of several Ab-degrading enzymes, including NEP and IDE. For example, a previous study performed in castrated rats unveiled that DHT administration can significantly increase neuronal expression of NEP through an androgen receptor (AR)-dependent mechanism, which in turn causes Ab degradation (46) . Similarly, in APP 23 mice with aromatase knockout, DHT has been shown to enhance Ab degradation via upregulating NEP (26) . Recently, new-generation selective AR modulators have exhibited potential therapeutic value by reducing Ab levels in the brain via increased levels and activity of IDE in AD animal models (47) . Moreover, studies have revealed that testosterone treatment can influence IDE levels (48) , suggesting the Ab-degrading role of androgens in the brain. However, further studies are needed to investigate the androgen-mediated neuroprotection and intracellular degradation of Ab, such as the ubiquitinproteasome pathway, the autophagy-lysosome pathway, and the endosome-lysosome pathway.
Clearance
Microglial phagocytosis
Microglia cells are resident macrophages in the brain and originate from myeloid/monocytic cells. They act as antigen-presenting cells during neuroinflammation and scavenger cells in neurodegeneration (49) . During the progression of AD, microglia are activated to migrate toward Ab plaques and to secrete numerous inflammatory mediators for Ab phagocytosis (50) . Reactive microglia extensively express ARs (51, 52) . It has been shown that androgen promotes microglia to phagocytose Ab 1-42 through upregulating the expression of formyl peptide receptor 2 and endothelin-converting enzyme 1c, which is involved in Ab uptake by microglia, suggesting that microglia activated by androgens are associated with Ab clearance (53) . Although the effect of androgens on neuroinflammation is still unclear, it is assumed that testosterone performs an immunosuppressive action in the acute inflammatory phase but exacerbates the neurodegenerative process in the progression of experimental autoimmune encephalomyelitis (54) . Presumably, androgen seems to be beneficial to the inflammatory response in early stages of AD pathogenesis, but it is detrimental once pathology has progressed. In addition, it is accepted that the anti-inflammatory effect of androgens is mediated by inhibiting the microglial activation and release of proinflammatory mediators such as TNF-a, IL-1b, and IL-6 (55), but the exact role of androgens in the microglia-mediated inflammation of AD is still unclear. Further studies are needed to investigate the effect of androgens on microglia and astrocyte activation, as well as Ab clearance by these cells.
CSF and BBB clearance
Ab can be cleared from the brain via various overlapping clearance systems, including CSF and BBB clearance. The majority of CSF is generated by the choroid plexus, which connects with fenestrated endothelium to form a vascular unit of capillaries responsible for the molecule/drug exchange located in the ventricles (41) . Ab uptake by the choroid plexus epithelium can remove it from the CSF into the blood, thus maintaining homeostasis of Ab in the brain extracellular fluid (56) . However, excessive Ab accumulation can lead to mitochondrial dysfunction, reactive oxygen species (ROS) overproduction, and oxidative damage to the choroid plexus epithelium and eventually compromise Ab clearance (57) . A recent study has revealed that DHT prevents the Ab-induced ROS generation in the choroid plexus epithelium and elevates the expression of the Ab scavenger transthyretin in an AR-dependent manner (58) . These results indicate that androgens can target the choroid plexus to promote Ab clearance from the CSF to the blood.
In addition, androgens seem to influence the elimination of Ab from the brain by transportation through the BBB. For example, chronic depletion of testosterone induced by castration in young male mice results in BBB leakage and thus impairs endothelial tight junctions that are essential for formation and maintenance of BBB (59) . Administration of testosterone to castrated mice restores the impermeability of the BBB and the integrity of the capillary endothelial tight junction (59), possibly because testosterone stimulates AR expression and its translocation into the nuclei (60) . Consistent with this finding, a study performed in SAMP8 mice, a model of cognitive decline with aging, has shown that treatment with both testosterone and DHT protects hippocampal vascular endothelial senescence against oxidative stress through upregulation of eNOS and SIRT1 (61) . Thus, it can be speculated that androgens might promote Ab elimination from the brain by protecting cerebrovascular endothelial cells from oxidative damage. Although these results suggest that androgens can maintain the function of these cells and the integrity of the BBB, whether androgens affect the Ab clearance by the BBB remains elusive.
Ab Toxicities Inhibited by Androgens
Oxidative stress
According to the amyloid cascade hypothesis, Ab deposition gives rise to mitochondrial toxicity, which leads to an impairment of energy production and oxidative stress (62) . The decline in bioenergetic activity and the increase in DNA oxidation exacerbate the pathological process of AD (63) . During aging, mitochondrial dysfunction is accompanied by a decline of testosterone level in the brain (64) . In addition, an age-related sex hormone decrease is associated with an increase of oxidative stress (65) . These results imply that androgens can regulate mitochondrial oxidative stress. In fact, it has been proposed that testosterone can maintain energy production through regulating the expression of nuclear and mitochondrial OXPHOS genes because both encode the subunits of mitochondrial chain complexes via sex hormone-responsive elements (66) . In addition, several recent studies have unveiled that testosterone protects mitochondrial function against oxidative damage by regulating the expression of mitochondrial ND1 and ND4 (mitochondrial DNA-encoded subunits of complex I) in neurons (67) , as well as neuroglobin (a hemoprotein) in astrocytes (68), respectively.
In parallel, testosterone has been shown to increase neuronal bioenergetic activity via upregulation of ATP levels, mitochondrial membrane potential, and basal mitochondrial respiration; moreover, it can modulate the redox homeostasis by improving mitochondrial antioxidant activity to alleviate excessive ROS (69) . The neuroprotective role of testosterone in Ab-induced mitochondrial dysfunction is further demonstrated in cellular models of AD overexpressing either APP/Ab or t protein. In this study, researchers found that testosterone can significantly diminish the bioenergetic deficits compared with other sex hormones, such as progesterone and estrogens (70) . Thus, these results suggest that androgen exerts its neuroprotective function via increasing mitochondrial bioenergetics and alleviating oxidative stress in AD. However, a clinical observation showed that endogenous testosterone levels were associated with cognitive impairment under elevated oxidative stress, suggesting that testosterone has deleterious effects under a high level of oxidative stress (71) . Thus, it is proposed that the level of oxidative stress defines the neuroprotective or neurotoxic function of androgens in neurodegenerative disease (72) , but it remains unproven in AD. Although the exact role of androgens on oxidative stress in the brain is still unknown, it can be speculated that androgens could maintain mitochondrial function to prevent oxidative damage to neurons.
Apoptosis
It is widely accepted that Ab can induce neuronal apoptosis through augmentation of oxidative damage (73) and direct binding to apoptotic factors and pathways (74, 75) . Previous evidence has demonstrated that oxidative stress-mediated cell apoptosis can be attenuated by testosterone administration in cerebellar granule cells (76) . In addition, several studies of neuron cultures have shown that androgen can reduce the apoptotic cell death induced by the aggregation of Ab peptides in an AR-mediated manner (77, 78) . As an apoptosis-inducing insult, Ab leads to neuronal apoptosis through activation of caspases, and this effect can be reversed by treatment with androgens (79) . The antiapoptotic mechanism of androgens involves MAPK/ERK, which contributes to phosphorylation-dependent inactivation of the proapoptosis factor Bcl-2-associated death protein (80) . The MAPK/ERK pathway is targeted by the selective AR modulator RAD140 that reduces apoptotic cell death induced by Ab, suggesting the neuroprotective action of endogenous androgens (81) . Further study performed on SH-SY5Y cells and primary cortical neuron cultures found that metabolites of testosterone function differently in antiapoptosis via modulation of ERK phosphorylation (82) . In this study, DHT can induce an initial rapid activation of ERK phosphorylation, but this effect was inhibited by 3a-diol, which modulates adverse consequences of prolonged ERK activation and caspase-3 cleavage resulting from Ab exposure (82) . Also, androgens can protect Ab-induced neurotoxicity by regulation of the phosphatidylinositol 3-kinase (PI3K)/ Akt signaling pathway (83) and activation of heat shock protein 70 (84) , both of which reduce cell apoptosis. Through rapid PI3K/Akt signaling, androgens regulate the Ab-mediated expression of apoptosis-related proteins, including bax, seladin 1, survivin, XIAP, and bcl-xl protein (85, 86) . Thus, these results indicate that androgen can prevent apoptosis to neurons mainly by a nongenomic mechanism of the AR involving activation of the MAPK/ERK and PI3K/Akt signaling pathways.
Moreover, androgens can maintain neuronal integrity and thus improve cognitive function. Recent studies have revealed that Ab impairs the synaptic structure and function of hippocampal neurons accompanied with a decreased expression of synaptic proteins, including synaptophysin, synaptotagmin, and synapsin 1 (27, 87) . These effects can be preserved by androgen administration, thus improving the cognitive performances in AD animal models (27, 88) . Thus, androgens can maintain the integrity of neurons and thus improve cognitive function in AD. Although the neuroprotective mechanisms of androgen in AD are not well understood, the action of androgen inhibiting Ab-induced apoptosis does matter.
Therapeutic implications
As mentioned above, androgen depletion in male 3xTg-AD mice significantly promotes Ab deposition and cognitive impairment, but this effect is prevented by androgen treatment (9, 23) . A further comparative study of sex hormones' influence on Ab level has proved that estradiol, testosterone, and DHT can significantly reduce Ab level, with testosterone being the most effective and estradiol the least effective (24) , indicating the accumulative effect of testosterone on Ab clearance. However, treatment with the nonaromatizable DHT in male castrated mice reduces the brain Ab levels that are not attenuated by treatment with estradiol (28) . One explanation might be that the aromatizable estradiol metabolized from testosterone is more bioactive than exogenous estradiol. Also, blocking testosterone conversion to estrogen with aromatase inhibitors results in hippocampal Ab accumulation in female mice, suggesting the Ab-lowering role of testosterone on females with AD (89) . Thus, these findings suggest that androgens can improve cognition of AD models through their anti-Ab effect. However, supplementation with testosterone in older male subjective memory complainers fails to change the plasma Ab levels (90) . Therefore, larger scale clinical investigations are needed to identify whether androgens exert the anti-Ab effect, which might promote the clinical application of testosterone replacement therapy (TRT) in patients with AD.
Altogether, testosterone exerts a neuroprotective role via the anti-Ab effect. However, the results of testosterone clinical trials on patients with AD are mixed. A pilot study performed on 10 men with AD who received testosterone substitution intramuscularly weekly for a year revealed that the treatment group had a significantly better visuospatial function and cognitive score compared with the controls (91) . Similar findings were further demonstrated in another study that evaluated the effect of TRT in 15 patients with AD at the 6-week follow-up who showed a significant improvement in spatial memory, constructional abilities, and verbal memory in the testosterone group (92). Thus, these small studies indicate that testosterone supplementation has a beneficial effect on cognitive function in AD. A recent larger study also observed a modest improvement in verbal memory in men with MCI after receiving testosterone treatment for 3 months (93) . Conversely, other studies revealed that testosterone administration has no significant impact on cognition in men with AD and early MCI (94, 95) . Recently, a 1-year testosterone trial study examining cognitive function in 493 men with ageassociated memory impairment has presented that testosterone produced no benefit in cognitive function tests involving visual memory, spatial memory, or executive functions (96) . Although androgen can exert anti-Ab function, other pathogenic factors and comorbidities can lead to severe cognitive impairment in patients with AD so that testosterone supplementation fails to restore cognitive function. Moreover, the activating effects and sensitivity of sex hormones on brain tissue decline with aging, and exogenous testosterone cannot function effectively. The heterogeneity in results is likely related to study design and methods as well as participants' age, baseline serum testosterone level, and cognitive status (97) . Another explanation might be that different individuals vary in degenerative changes in the brain structures and functions. Thus, randomized controlled trials of a longer duration and larger sample size on men with AD receiving TRT should be conducted to identify its benefits on cognitive function.
Conclusion
Although a causal relationship between androgens and AD has yet to be definitively shown, findings from both human and experimental paradigms indicate that agerelated depletion of androgen in males increases vulnerability of the aging brain to Ab accumulation. Of interest, the inverse relationship between testosterone levels and Ab deposition in the brain seems to mainly emerge within patients with MCI. Moreover, recent interventional studies about testosterone in aging men with different severities of cognitive impairment have shown inconsistent results, and the study population is still not established. Thus, future testosterone clinical trials should be focused on the MCI population. Currently, the utility of plasma Ab levels to predict AD is still controversial. Considering that the plasma Ab ratio and brain amyloid deposition can be reflected by plasma and brain testosterone levels, future studies are essential to investigate the association between testosterone levels and AD pathology. In addition, extensive studies have investigated the role of estrogens in AD pathologies, but less attention has been paid to the role of androgen in Ab metabolism and toxicity. It is concluded that androgen is able to exert its neuroprotective role through modulation of the metabolic pathway of Ab (Fig. 1) and attenuation of Ab-induced neurotoxicity (Fig. 2) . Thus, continued elucidation of these pathways and mechanisms may provide novel insights into the development of AD as well as therapeutic approaches for its prevention and treatment. The results of TRT on patients with AD are conflicting. It can be speculated that in the early stage of AD, physiological testosterone concentration can prevent cognitive impairment from pathological factors (e.g., toxic Ab), but androgen depletion with aging or ADT might make these patients lose their "neuroprotective umbrella," which could be the reason that TRT fails to reverse cognitive dysfunction. Thus, testosterone trials of a larger scale and a longer duration on men with varying severity of AD should be ongoing to identify its effects on cognitive function.
